Abbott has acquired a majority of the shares of Kos Pharmaceuticals, Inc. for $3.7 billion. The acquisition follows a scheduled expiration on December 12th for the purchase of all outstanding common stock of Kos. Abbott’s shares now represent approximately 91.4% of Kos’ outstanding shares.

The merger is expected to occur within the next few days.